These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 16487834)

  • 1. The value of selectivity.
    Colombo A; Stankovic G
    J Am Coll Cardiol; 2006 Feb; 47(4):719-20. PubMed ID: 16487834
    [No Abstract]   [Full Text] [Related]  

  • 2. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions.
    Gambhir DS; Mukhopadhyay S
    Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774
    [No Abstract]   [Full Text] [Related]  

  • 3. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries.
    Goldschmidt-Clermont PJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

  • 5. Using eptifibatide in patients undergoing coronary angioplasty with acute myocardial infarction.
    Wong CB
    Catheter Cardiovasc Interv; 2003 Nov; 60(3):423-4; author reply 424. PubMed ID: 14571498
    [No Abstract]   [Full Text] [Related]  

  • 6. Eptifibatide in percutaneous coronary intervention. A review.
    Dery JP; O'Shea JC; Tcheng JE
    Minerva Cardioangiol; 2002 Oct; 50(5):531-46. PubMed ID: 12384635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Platelet glycoprotein IIb/IIIa blockade with eptifibatide in angioplasty followed by stent implantation at 6 month in the ESPRIT study].
    Fresco C
    Ital Heart J Suppl; 2001 Sep; 2(9):1029-30. PubMed ID: 11675826
    [No Abstract]   [Full Text] [Related]  

  • 8. [Impact of GP IIb/IIIa antagonists in interventional cardiology].
    Scheller B; Hennen B; Böhm M; Nickenig G
    Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimal antiplatelet therapy during percutaneous coronary interventions includes glycoprotein IIb/IIIa inhibitors just eliminate the infusion.
    Mahmud E; Prasad A
    J Am Coll Cardiol; 2009 Mar; 53(10):846-8. PubMed ID: 19264240
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
    Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
    J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
    Saw J; Moliterno DJ
    Coron Artery Dis; 2003 Aug; 14(5):373-80. PubMed ID: 12878902
    [No Abstract]   [Full Text] [Related]  

  • 12. Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
    Ramanathan A; Kleiman NS
    Indian Heart J; 1998 Oct; 50 Suppl 1():45-56. PubMed ID: 9824907
    [No Abstract]   [Full Text] [Related]  

  • 13. Care of the patient receiving ReoPro following angioplasty.
    Brezina K; Murphy M; Stonner T
    J Invasive Cardiol; 1994; 6 Suppl A():38A-42A; discussion 54A-56A. PubMed ID: 10155094
    [No Abstract]   [Full Text] [Related]  

  • 14. The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide.
    Moliterno DJ; Ziada KM
    J Am Coll Cardiol; 2008 Feb; 51(5):536-7. PubMed ID: 18237681
    [No Abstract]   [Full Text] [Related]  

  • 15. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 16. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
    Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
    Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
    [No Abstract]   [Full Text] [Related]  

  • 17. Stents and IIb/IIIa receptor blockers combined: usefulness in various types of coronary artery disease.
    van der Wieken LR
    Semin Interv Cardiol; 1999 Jun; 4(2):77-83. PubMed ID: 10473876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IIb/IIIa platelet inhibitors in the management of coronary artery disease.
    Talley JD
    J Ark Med Soc; 1996 Oct; 93(5):237-9. PubMed ID: 8908943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.